← ANALYST RATINGS · TIPRANKS
Beta Bionics, Inc. (BBNX): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy4 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $23.62, the highest $30.00, the lowest $16.00. The average is +44.5% from the last price of $16.35.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $19.50 → $18.00−7.7% | Buy | +10.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $18.50 → $17.50−5.4% | Hold | +7.0% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $18.50 → $17.50−5.4% | Hold | +7.0% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $17.50 → $17.00−2.9% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $19.00 → $18.00−5.3% | Buy | +10.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $18.00 → $17.00−5.6% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Michael Toomey★★★★★★★★★★#10023 · hits 29% · avg −6.8% | Jefferies | $30.00 | Buy | +83.5% | Initiated | 12.10.26on TipRanks 05:45 | +1.4%next day −0.9% | ↗ |
| Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% | Nephron | $30.00 | Buy | +83.5% | Initiated | 06.10.26on TipRanks Oct 7 05:20 | −2.2%next day −2.7% · 5 days −4.9% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $23.00 → $28.00+21.7% | Buy | +71.3% | Assigned | 24.09.26on TipRanks 07:30 | −1.9%next day −1.7% · 5 days −12.9% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $28.00 | Buy | +71.3% | Initiated | 23.09.26on TipRanks 05:10 | −2.0%next day −1.9% · 5 days −13.8% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $25.00 | Buy | +52.9% | Reiterated | 22.09.26on TipRanks 09:10 | +3.5%next day −2.0% · 5 days −13.7% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $27.00 | Buy | +65.1% | Reiterated | 17.09.26on TipRanks Sep 14 08:45 | +1.4%next day +15.4% · 5 days +29.8% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $20.00 → $22.00+10.0% | Buy | +34.6% | Reiterated | 15.09.26on TipRanks 22:05 | +15.8%next day −4.5% · 5 days −2.0% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $14.00 → $16.00+14.3% | Hold | −2.1% | Reiterated | 15.09.26on TipRanks 07:05 | +15.4%next day +15.8% · 5 days +16.3% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $22.00 → $25.00+13.6% | Buy | +52.9% | Reiterated | 15.09.26on TipRanks 06:45 | +15.4%next day +15.8% · 5 days +16.3% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $18.00 → $20.00+11.1% | Hold | +22.3% | Reiterated | 14.09.26on TipRanks Sep 15 06:10 | +1.4%next day +15.4% · 5 days +29.8% | ↗ |
| Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% | TD Cowen | $16.00 → $18.00+12.5% | Hold | +10.1% | Reiterated | 14.09.26on TipRanks 12:10 | +1.4%next day +15.4% · 5 days +29.8% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Hold | — | Reiterated | 14.09.26on TipRanks 11:35 | +1.4%next day +15.4% · 5 days +29.8% | ↗ |
| Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9% | Ladenburg Thalmann & Co. | $30.40 | Buy | +85.9% | Reiterated | 30.07.26on TipRanks 09:30 | −7.6%next day −10.8% · 5 days −4.7% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $20.00 | Buy | +22.3% | Reiterated | 30.07.26on TipRanks 06:57 | −7.6%next day −10.8% · 5 days −4.7% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $17.00 → $19.00+11.8% | Buy | +16.2% | Assigned | 15.07.26on TipRanks 06:30 | −0.4%next day +0.8% · 5 days −2.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Beta Bionics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $23.20 at a price of $18.98 (+22.2%); now: $24.57 at $16.35 (+50.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 2 | 7 | 5 |
| Hold | 3 | 3 | 3 | 3 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.52 (from $-0.59 to $-0.42). Last quarter: $-0.53.
Sales
Next quarter’s sales estimate — $35M (from $34M to $36M). Last quarter: $32M.
Best top-analyst consensus in the sector · General
About Beta Bionics, Inc.
- CEO: Sean T. Saint
- Employees: 422
- 11 Hughes, Irvine, CA, 92618, US
- www.betabionics.com
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Data from the stock’s TipRanks forecast page, read 66 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗